|Articles|March 1, 2017
March 2017: Big Data, Big Opportunity in Life Sciences
Author(s)LexisNexis
The big data transformation is poised to seep through the life sciences universe, promising to eliminate hundreds of billions of dollars of annual costs in the U.S. biopharmaceutical segment alone.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Redefining Obesity Success in the GLP-1 Era: Q&A with Brian Hilberdink
2
FDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010
3
Additive Manufacturing's Application in Pharma and Biotech
4
Pharma Funding Roudup: Kardigan Announces $400 Million Initial IPO, cAMPfield Launches with $180 million Series A
5
